‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells
Cellular immunotherapy is revolutionizing cancer treatment. However, treatments created from each patient’s cells are complex, costly, and limited by the number and quality of killer T cells that can be isolated from and expanded for re-infusion into each patient.
In this paper, Cartherics reports on progress in manufacturing the key components from donor cells from umbilical cord blood.
Nicholas Boyd, Kellie Cartledge, Huimin Cao, Vera Evtimov, Aleta Pupovac, Alan Trounson and Richard Boyd.